Latest Industry Insights

Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.

Through a series of exclusive interviews with world-renowned scientists and bioethicists, Technology Networks Explores the CRISPR Revolution will investigate the ground-breaking research taking place in the CRISPR space, CRISPR "controversies" and whether the CRISPR technology looks set to fulfil its promise of revolutionizing science.

10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

We recently had the pleasure of speaking with Martin Gosling, Enterprise Therapeutics’ CSO and Professor of Molecular Pharmacology at the University of Sussex. Martin highlights the respiratory diseases Enterprise Therapeutics primarily focus on and the new disease modifying therapies they have in development.

Long sequences of DNA are a key requirement for researchers to be able to develop novel synthetic biomolecules. However, assembling long sequences can prove problematic and slow down the process of gene assembly. GenBrick™ utilizes a novel proprietary technology to enable accurate one-step DNA assembly. We spoke with Cedric Wu, Ph.D., GenScript Sr. Director of R&D to learn more about the capabilities of GenBrick™.

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.

We recently spoke with Dr Marian Rehak, VP of Research and Development at Sphere Fluidics, to learn more about the importance of single cell analysis. Marian touches on some of the common challenges encountered and highlights some of the key applications.

NRGene recently announced the launch of DeNovoMAX, an enhanced version of its flagship product DeNovoMAGIC, for whole genome assembly. As part of the DeNovo assembly product suite, DeNovoMAX aims to take agricultural research further by empowering breeding and maximizing agricultural yield. We spoke with Gal Ramot, Marketing Director at NRGene Ltd to learn about the applications of DeNovoMAX and how it has been built to crack the most "complex of genomes".

In this interview, Aaron Hudson, Vice President & General Manager, Global Marketing & Strategy at SCIEX, discusses why precision quantification, specifically quantitative mass spectrometry (MS), is the best approach for measuring the transition from "wellness" to illness.